Compare Incyte Corporation (INCY) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Schwab US Large Cap Growth ETF — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Schwab US Large Cap Growth ETF trades at $34.25. The key difference: Incyte Corporation is trading nearer its 52-week high, Schwab US Large Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SCHG | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $35.30 |
52-Week Low | $67.38 | $28.10 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SCHG trades at $34.15, down slightly by 0.09% today, with a bullish technical signal driven by moving averages. The ETF offers concentrated exposure to large-cap U.S. growth stocks, particularly in technology and AI, with a low 0.04% expense ratio. Recent news highlights strong fundamentals and AI-driven growth potential, though heavy concentration in top holdings like Nvidia, Apple, and Microsoft presents both opportunity and risk.
Outlook remains positive for long-term growth investors, supported by AI capital expenditure trends and low costs. Key risks include high valuation sensitivity, interest rate impacts, and lack of diversification. Analyst sentiment is mixed, with some caution on recent underperformance versus broader markets despite strong thematic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
